La buprénorphine soulage les symptômes de sevrage, tandis que le naloxone bloque les effets euphorisants.
BuprénorphineNaloxone
#2
Quelle est la posologie recommandée ?
La posologie varie, mais commence souvent par 4 mg de buprénorphine et 1 mg de naloxone.
PosologieBuprénorphine
#3
Combien de temps dure le traitement ?
Le traitement peut durer plusieurs mois à plusieurs années, selon la réponse du patient.
TraitementDépendance aux opioïdes
#4
Quels sont les objectifs du traitement ?
Les objectifs incluent la réduction des cravings, l'amélioration de la qualité de vie et la prévention des rechutes.
Objectifs de traitementDépendance aux opioïdes
#5
Le traitement nécessite-t-il un suivi médical ?
Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les progrès.
Suivi médicalDépendance aux opioïdes
Complications
5
#1
Quelles complications peuvent survenir avec ce traitement ?
Les complications incluent des problèmes respiratoires, des réactions allergiques et des dépendances croisées.
ComplicationsBuprénorphine
#2
Comment gérer les complications liées au traitement ?
La gestion implique un suivi médical régulier et des ajustements de la posologie si nécessaire.
Gestion des complicationsSuivi médical
#3
Les complications sont-elles fréquentes ?
Les complications sont rares mais peuvent survenir, surtout en cas de mauvaise utilisation.
ComplicationsDépendance aux opioïdes
#4
Quels sont les risques d'interactions médicamenteuses ?
Des interactions peuvent survenir avec d'autres dépresseurs du système nerveux central.
Interactions médicamenteusesBuprénorphine
#5
Comment reconnaître une réaction allergique ?
Les signes incluent éruption cutanée, démangeaisons, et gonflement du visage ou de la gorge.
Réaction allergiqueBuprénorphine
Facteurs de risque
5
#1
Quels sont les facteurs de risque de dépendance ?
Les facteurs incluent des antécédents familiaux, des troubles mentaux et l'accès facile aux opioïdes.
Facteurs de risqueDépendance aux opioïdes
#2
L'âge influence-t-il le risque de dépendance ?
Oui, les jeunes adultes sont souvent plus à risque en raison de comportements exploratoires.
ÂgeDépendance aux opioïdes
#3
Les antécédents de traumatismes augmentent-ils le risque ?
Oui, les personnes ayant subi des traumatismes sont plus susceptibles de développer une dépendance.
TraumatismesDépendance aux opioïdes
#4
Le stress peut-il être un facteur de risque ?
Oui, le stress chronique peut augmenter le risque de dépendance aux opioïdes.
StressDépendance aux opioïdes
#5
Les prescriptions excessives d'opioïdes sont-elles un risque ?
Oui, des prescriptions excessives augmentent le risque de dépendance et d'abus.
Prescription d'opioïdesDépendance aux opioïdes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Association de buprénorphine et de naloxone : Questions médicales les plus fréquentes",
"headline": "Association de buprénorphine et de naloxone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Association de buprénorphine et de naloxone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-06",
"dateModified": "2026-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Association de buprénorphine et de naloxone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Association médicamenteuse",
"url": "https://questionsmedicales.fr/mesh/D004338",
"about": {
"@type": "MedicalCondition",
"name": "Association médicamenteuse",
"code": {
"@type": "MedicalCode",
"code": "D004338",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D26.310"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Association de buprénorphine et de naloxone",
"alternateName": "Buprenorphine, Naloxone Drug Combination",
"code": {
"@type": "MedicalCode",
"code": "D000069479",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Pouya Azar",
"url": "https://questionsmedicales.fr/author/Pouya%20Azar",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada."
}
},
{
"@type": "Person",
"name": "Cameron Grant",
"url": "https://questionsmedicales.fr/author/Cameron%20Grant",
"affiliation": {
"@type": "Organization",
"name": "British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, British Columbia, V6Z 2A9, Canada."
}
},
{
"@type": "Person",
"name": "Andrew Kestler",
"url": "https://questionsmedicales.fr/author/Andrew%20Kestler",
"affiliation": {
"@type": "Organization",
"name": "Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada."
}
},
{
"@type": "Person",
"name": "Paxton Bach",
"url": "https://questionsmedicales.fr/author/Paxton%20Bach",
"affiliation": {
"@type": "Organization",
"name": "British Columbia Centre on Substance Use, Vancouver, British Columbia, Canada."
}
},
{
"@type": "Person",
"name": "Kanna Hayashi",
"url": "https://questionsmedicales.fr/author/Kanna%20Hayashi",
"affiliation": {
"@type": "Organization",
"name": "British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, British Columbia, V6Z 2A9, Canada; Faculty of Health Sciences, Simon Fraser University, 888 University Drive, Burnaby, British Columbia, V5A 1S6, Canada."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Disparities in Emergency Department Naloxone and Buprenorphine Initiation.",
"datePublished": "2023-06-30",
"url": "https://questionsmedicales.fr/article/37527392",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5811/westjem.58636"
}
},
{
"@type": "ScholarlyArticle",
"name": "Medicare coverage of buprenorphine-naloxone film surrounding generic entry.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37616154",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.37765/ajmc.2023.89413"
}
},
{
"@type": "ScholarlyArticle",
"name": "Buprenorphine/naloxone - one formulation that doesn't fit all: a case report.",
"datePublished": "2024-07-30",
"url": "https://questionsmedicales.fr/article/39080714",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12954-024-01054-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of opioid use disorder treatment outcomes in patients receiving split daily versus once daily dosing of buprenorphine-naloxone.",
"datePublished": "2023-11-06",
"url": "https://questionsmedicales.fr/article/37939905",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.josat.2023.209209"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone.",
"datePublished": "2024-08-12",
"url": "https://questionsmedicales.fr/article/39133511",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1001/jama.2024.11501"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Préparations pharmaceutiques",
"item": "https://questionsmedicales.fr/mesh/D004364"
},
{
"@type": "ListItem",
"position": 3,
"name": "Association médicamenteuse",
"item": "https://questionsmedicales.fr/mesh/D004338"
},
{
"@type": "ListItem",
"position": 4,
"name": "Association de buprénorphine et de naloxone",
"item": "https://questionsmedicales.fr/mesh/D000069479"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Association de buprénorphine et de naloxone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Association de buprénorphine et de naloxone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Association de buprénorphine et de naloxone",
"description": "Comment diagnostiquer une dépendance aux opioïdes ?\nQuels tests sont utilisés pour évaluer la dépendance ?\nQuels signes cliniques indiquent une dépendance ?\nComment évaluer la gravité de la dépendance ?\nQuel professionnel peut diagnostiquer cette dépendance ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Association de buprénorphine et de naloxone",
"description": "Quels sont les symptômes de la dépendance aux opioïdes ?\nComment se manifestent les symptômes de sevrage ?\nQuels effets secondaires peuvent survenir avec ce traitement ?\nLes symptômes varient-ils selon les individus ?\nQuels sont les signes d'une overdose ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Association de buprénorphine et de naloxone",
"description": "Comment prévenir la dépendance aux opioïdes ?\nQuels programmes existent pour prévenir la dépendance ?\nLes médecins jouent-ils un rôle dans la prévention ?\nComment sensibiliser les jeunes aux risques ?\nQuelles alternatives aux opioïdes existent pour la douleur ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Association de buprénorphine et de naloxone",
"description": "Comment fonctionne l'association buprénorphine-naloxone ?\nQuelle est la posologie recommandée ?\nCombien de temps dure le traitement ?\nQuels sont les objectifs du traitement ?\nLe traitement nécessite-t-il un suivi médical ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Association de buprénorphine et de naloxone",
"description": "Quelles complications peuvent survenir avec ce traitement ?\nComment gérer les complications liées au traitement ?\nLes complications sont-elles fréquentes ?\nQuels sont les risques d'interactions médicamenteuses ?\nComment reconnaître une réaction allergique ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Association de buprénorphine et de naloxone",
"description": "Quels sont les facteurs de risque de dépendance ?\nL'âge influence-t-il le risque de dépendance ?\nLes antécédents de traumatismes augmentent-ils le risque ?\nLe stress peut-il être un facteur de risque ?\nLes prescriptions excessives d'opioïdes sont-elles un risque ?",
"url": "https://questionsmedicales.fr/mesh/D000069479#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dépendance aux opioïdes ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des critères cliniques, l'historique médical et des tests de dépistage."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la dépendance ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des questionnaires standardisés et des évaluations cliniques sont utilisés pour évaluer la dépendance."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent une dépendance ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des cravings, des comportements compulsifs et des symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Comment évaluer la gravité de la dépendance ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gravité est évaluée par la fréquence d'utilisation et l'impact sur la vie quotidienne."
}
},
{
"@type": "Question",
"name": "Quel professionnel peut diagnostiquer cette dépendance ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médecin, un psychiatre ou un spécialiste en toxicomanie peut poser le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la dépendance aux opioïdes ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des cravings, des changements d'humeur, et des problèmes de santé physique."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les symptômes de sevrage ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes de sevrage incluent anxiété, douleurs musculaires, et insomnie."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir avec ce traitement ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, constipation, et somnolence."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon les individus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la durée et de l'intensité de la dépendance."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une overdose ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, respiration lente, et perte de conscience."
}
},
{
"@type": "Question",
"name": "Comment prévenir la dépendance aux opioïdes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut l'éducation, la gestion de la douleur et l'utilisation prudente des opioïdes."
}
},
{
"@type": "Question",
"name": "Quels programmes existent pour prévenir la dépendance ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des programmes éducatifs et de sensibilisation sont disponibles pour informer sur les risques."
}
},
{
"@type": "Question",
"name": "Les médecins jouent-ils un rôle dans la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les médecins doivent évaluer les risques avant de prescrire des opioïdes."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser les jeunes aux risques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes de sensibilisation et des ateliers dans les écoles peuvent aider."
}
},
{
"@type": "Question",
"name": "Quelles alternatives aux opioïdes existent pour la douleur ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements non opioïdes comme les anti-inflammatoires et la thérapie physique sont disponibles."
}
},
{
"@type": "Question",
"name": "Comment fonctionne l'association buprénorphine-naloxone ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "La buprénorphine soulage les symptômes de sevrage, tandis que le naloxone bloque les effets euphorisants."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie recommandée ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie, mais commence souvent par 4 mg de buprénorphine et 1 mg de naloxone."
}
},
{
"@type": "Question",
"name": "Combien de temps dure le traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement peut durer plusieurs mois à plusieurs années, selon la réponse du patient."
}
},
{
"@type": "Question",
"name": "Quels sont les objectifs du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les objectifs incluent la réduction des cravings, l'amélioration de la qualité de vie et la prévention des rechutes."
}
},
{
"@type": "Question",
"name": "Le traitement nécessite-t-il un suivi médical ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour ajuster le traitement et surveiller les progrès."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ce traitement ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des problèmes respiratoires, des réactions allergiques et des dépendances croisées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au traitement ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion implique un suivi médical régulier et des ajustements de la posologie si nécessaire."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, surtout en cas de mauvaise utilisation."
}
},
{
"@type": "Question",
"name": "Quels sont les risques d'interactions médicamenteuses ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interactions peuvent survenir avec d'autres dépresseurs du système nerveux central."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent éruption cutanée, démangeaisons, et gonflement du visage ou de la gorge."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque de dépendance ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles mentaux et l'accès facile aux opioïdes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de dépendance ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes adultes sont souvent plus à risque en raison de comportements exploratoires."
}
},
{
"@type": "Question",
"name": "Les antécédents de traumatismes augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant subi des traumatismes sont plus susceptibles de développer une dépendance."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut augmenter le risque de dépendance aux opioïdes."
}
},
{
"@type": "Question",
"name": "Les prescriptions excessives d'opioïdes sont-elles un risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des prescriptions excessives augmentent le risque de dépendance et d'abus."
}
}
]
}
]
}
British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, British Columbia, V6Z 2A9, Canada; Faculty of Health Sciences, Simon Fraser University, 888 University Drive, Burnaby, British Columbia, V5A 1S6, Canada.
Publications dans "Association de buprénorphine et de naloxone" :
British Columbia Centre on Substance Use, 400-1045 Howe St, Vancouver, British Columbia, V6Z 2A9, Canada; Department of Medicine, University of British Columbia, 667-1081 Burrard St, Vancouver, British Columbia, V6Z 1Y6, Canada.
Publications dans "Association de buprénorphine et de naloxone" :
Addictions and Concurrent Disorders Research Group, Department of Psychiatry, Institute of Mental Health, University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Association de buprénorphine et de naloxone" :
Prescribing of buprenorphine and naloxone in the emergency department (ED) has been shown to be an effective intervention. The purpose of this study was to determine the frequency of prescribing of na...
We used a national electronic health record database to identify patients with opioid poisoning or overdose presenting between January 2019-December 2021. Patients who were prescribed naloxone or bupr...
We found 74,004 patients in the database whom we identified as presenting to the ED with an opioid poisoning or overdose. Overall, 22.8% were discharged with a prescription for naloxone, while 0.9% of...
Despite evidence supporting its use, buprenorphine is not prescribed from the ED in a substantial proportion of patients. Naloxone is prescribed to a higher percentage, although still a minority of pa...
To investigate trends in Medicare coverage of buprenorphine-naloxone film before and after the FDA approval of its first generic versions....
This study used data from the Part D Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files from 2015 to 2022, which provide information on all stand-alone Medicare/Medicare...
We examined the percentage of plans that provided coverage of brand-name and generic buprenorphine-naloxone films with strength 8 mg/2 mg during 2015-2022. Median out-of-pocket (OOP) cost for a 30-day...
Generic buprenorphine-naloxone film was covered by 82% of Medicare Part D plans in 2020, 2 years after market entry. Coverage of brand-name Suboxone film decreased from 76% in 2019 to 42% in 2020. The...
Medicare Part D plan formularies replaced brand-name buprenorphine-naloxone films with the newly approved generic versions. This was accompanied by a substantial decrease in estimated OOP cost faced b...
Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when...
We present a patient whose adverse post-administration side effects on SL buprenorphine/naloxone resolved with transition to SL buprenorphine monoproduct....
Naloxone can be detected in nearly all patients taking SL buprenorphine/naloxone, though with apparent variability in clinical effect. In a minority of patients, naloxone can contribute to adverse and...
In clinical practice, sublingual (SL) buprenorphine-naloxone is prescribed as once daily or split daily dosing for the management of opioid use disorder (OUD). Evidence is lacking that assesses how sp...
This retrospective analysis included adult outpatients prescribed treatment with SL buprenorphine-naloxone for OUD between July 1, 2016, and March 1, 2020. The study excluded patients with sickle cell...
The study screened eight-hundred and seven patients, and included 250 patients newly prescribed SL buprenorphine-naloxone. Fifty-seven patients (22.8 %) were prescribed once daily dosing and 193 patie...
In this study, patients receiving once daily buprenorphine-naloxone had similar treatment outcomes to patients receiving split dosing. Further controlled studies are necessary to evaluate which patien...
Buprenorphine combined with naloxone is commonly used to treat opioid use disorders outside of pregnancy. In pregnancy, buprenorphine alone is generally recommended because of limited perinatal safety...
To compare perinatal outcomes following prenatal exposure to buprenorphine with naloxone vs buprenorphine alone....
Population-based cohort study using health care utilization data from Medicaid-insured beneficiaries in the US from 2000 to 2018. The cohort was restricted to pregnant individuals linked to their live...
Use of buprenorphine with naloxone vs buprenorphine alone during the first trimester based on outpatient dispensings....
Outcomes included major congenital malformations, low birth weight, neonatal abstinence syndrome, neonatal intensive care unit admission, preterm birth, respiratory symptoms, small for gestational age...
This study identified 3369 pregnant individuals exposed to buprenorphine with naloxone during the first trimester (mean [SD] age, 28.8 [4.6] years) and 5326 exposed to buprenorphine alone or who switc...
There were similar and, in some instances, more favorable neonatal and maternal outcomes for pregnancies exposed to buprenorphine combined with naloxone compared with buprenorphine alone. For the outc...
Limited research has explored sex differences in opioid use disorder medication (MOUD) treatment outcomes. The purpose of this study was to examine MOUD initiation onto buprenorphine-naloxone (BUP-NX)...
Using data from a 24-week open-label comparative effectiveness trial of BUP-NX or XR-NTX, this study examined MOUD initiation (i.e., receiving a minimum one XR-NTX injection or first BUP-NX dose) and ...
In the intent-to-treat sample, the odds of treatment initiation failure were not significantly different by sex. In the subsample of successful MOUD initiates, the effect of treatment on employment at...
Further research should explore how to integrate employment support into OUD treatment to improve patient outcomes, particularly among women....
The current study addressed gaps in the literature by examining sex differences in MOUD initiation and diverse treatment outcomes in a large, national sample....
Buprenorphine/naloxone (BUP-NX) and methadone are used to treat opioid use disorder (OUD), yet there is insufficient evidence on the impact of doses on interventions' effectiveness and safety when tre...
We explored associations between methadone and BUP-NX doses and treatment outcomes using data from OPTIMA, a 24-week, pragmatic, open-label, multicenter, pan-Canadian, randomized controlled, two-arm p...
The mean (SD) highest BUP-NX and methadone dose were 17.31 mg/day (8.59) and 67.70 mg/day (34.70). BUP-NX and methadone doses were not associated with opioid-positive UDS percentages or AEs. Methadone...
Methadone dose was associated with higher retention, which may be related to its full µ-opioid receptor agonism. Future research should notably ascertain the effect of pace of titration on a wide rang...
Our results extend previous findings of high doses of methadone increasing retention to be applied in our population using opioids other than heroin, including highly potent opioids....
Opioid use disorder is a major public health concern that accounts for a high number of potential years of life lost. Buprenorphine/naloxone is a recommended treatment for opioid use disorder that can...
In this quality improvement initiative, we supported local ED teams to offer buprenorphine/naloxone to eligible patients presenting to the ED with suspected opioid use disorder and refer these patient...
The program was implemented at 107 sites across Alberta during our evaluation period. Buprenorphine/naloxone initiations in the ED increased post-intervention at most sites with baseline data availabl...
A standardized provincial approach to initiating buprenorphine/naloxone in the ED for patients living with opioid use disorder was spread to 107 sites with dedicated program support staff and adjustme...
Buprenorphine is an effective and safe treatment for opioid use disorder, but the requirement for moderate opioid withdrawal symptoms to emerge prior to initiation is a significant treatment barrier....
We report on two cases of hospitalized patients with severe, active opioid use disorder, in which we initiated treatment with transdermal buprenorphine over 48 h, followed by the administration of a s...
This provides preliminary evidence for a rapid induction strategy that may improve tolerability, caregiver burden, and treatment retention as compared to previous induction strategies....
Breastfeeding among lactating people with opioid use disorder taking buprenorphine monotherapy is generally accepted, as low concentrations of buprenorphine and metabolites in human milk have been wel...
To determine the concentrations of buprenorphine and naloxone and their primary metabolites in human milk, maternal plasma, and infant plasma, among lactating buprenorphine-naloxone maintained people ...
Four lactating buprenorphine-naloxone maintained people provided plasma and human milk samples on Days 2, 3, 4, 14, and 30 postpartum. Infant plasma was obtained on Day 14....
Concentrations of buprenorphine, norbuprenorphine and their glucuronide metabolites were present in maternal plasma and human milk at low concentrations, consistent with previous research in lactating...
Results support the use of buprenorphine-naloxone by lactating people who meet appropriate criteria for breastfeeding....